Jan Lundahl, the head of life sciences for Nordic private equity firm CapMan, has resigned after seven years with the firm. He will be replaced by his life sciences deputy partner, Johan Bennarsten, effective from Monday.
Lundahl helped establish CapMan’s life sciences arm, raising €88 million across four life science-specific funds and leading investment into 12 portfolio companies including: foetus monitoring company Neoventa Medical; ProstaLund, a prostate treatment company; and QuickCool, a company that attempts to prevent brain damage.
His life sciences experience spans three decades. Prior to CapMan, he’d been a senior partner with Swedish venture firm Swedestart Management, which was acquired by CapMan in 2002. He is also credited with founding the first venture capital firm specialising in life science in Sweden together with Investor AB in 1987.
Lundhal’s next move is unknown and CapMan was not available for comment at press time.
Life sciences is one of six investment areas covered by Nordic-focused CapMan, which manages around €3 billion across buyout, technology, Russian, public market and real estate funds. In January CapMan held a €203 million first close on its ninth buyout fund, which will target Nordic midmarket companies.